Patrick is an emeritus professor working in trial design and analysis and has spent most of his working life applying and researching statistical methods in medicine and allied disciplines. MRC Clinical Trials Unit at UCL

Congratulations to Prof Patrick Royston , who on 17th April was ranked #89 in the world ranking and #4 in United Kingdom. He was also recognised with Research.com's Mathematics Leader Award for 2024!
MRC Clinical Trials Unit at UCL

Agree, most-deserving: wonderful to see!
Congratulations Max Parmar

Juan Brufal

On a day when the new iPads are released with all the potential that harnessing AI provides, I reflect on the ethical aspects which must be considered in its application to my research interest, supportive care in cancer.
onlinelibrary.wiley.com/share/author/Q…

👏 Congratulations Susan Harden Kim Chiew Jeremy Millar Shalini Vinod

🎉 Your work on 'Quality Indicators for Radiation Oncology' has been recognised as one of our #TopDownloaded articles.

#OpenAccess #quality #radonc Wiley Biomedical Science

ow.ly/eKgH50RbVJ1

A word we hear a lot about currently in the trials world is #Estimands .  But what are they and why are they useful? 1/8
#MethodologyMonday #85

Exciting news for #ProstateCancer patients! 🔬📚

New research from the @ANZUPTrials led #ENZAp study published in the Lancet Oncology shows that combining two complementary targeted treatments can enhance anticancer activity and improve survival outcomes.

Read the…

Shout out to evervone who can still remember their childhood phone number but can't remember the password they created yesterday.

Apple Tree, I, 1912 botfrens.com/collections/10…

☁️ Percentage average yearly cloud cover:

🇮🇸 Iceland: 84.4%
🇬🇱 Greenland: 83.7%
🇳🇴 Norway: 81.5%
🇮🇪 Ireland: 80.1%
🇫🇮 Finland: 79.6%
🇬🇧 UK: 78.4%
🇸🇪 Sweden: 78.2%
🇳🇱 Netherlands: 74.4%
🇩🇰 Denmark: 72.2%
🇩🇪 Germany: 71.5%
🇵🇱 Poland: 71.1%
🇨🇿 Czechia: 70.5%
🇨🇦 Canada: 69.2%
🇷🇺…

Do apply! Access to Oncology Medicines (ATOM) has the potential to democratize access to cancer medicines globally. Be part of this impact! Union for International #CancerControl gilberto lopes Cary Adams Professor Jeff Dunn AO

APRIL IN CHANDIGARH
New leaves, New hope!
#BaisakhiFestival
Happy Baisakhi 🌾🌾🌾🌳🌳🌼🏵🌻
#positivity #hope
#Chandigarh

ENZA-p trial The Lancet Oncology
authors.elsevier.com/a/1iw3e5EIIgPd…
Enzalutamide + adaptive-dosed (2 or 4) 177 Lu-PSMA617 vs enza alone in mCRPC.
Biomarker guided combination therapy works!
Better response depth/duration with no added tox. ANZUP NHMRC CTC Movember Australia St Vincent's Sydney

Andrei Gafita uses his prior The Lancet Oncology LuPSMA nomogram to analyse the #TheraP study... Results here:
euoncology.europeanurology.com/article/S2588-…

'We found that the statistical models can predict patient survival, and aid in determining whether Lu-PSMA therapy or cabazitaxel yields a higher…

Congratulations Professor Ambassador!

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

Clinical cancer research and care are evolving at unprecedented speeds. Join us at ASCO Breakthrough to discover the latest cutting-edge advances spanning multiple disease sites that will keep you at the forefront of innovation that is shaping clinical cancer care.

Great to see @ANZUPTrials #P3BEP study enrol over 300 participants, reaching over 85% full recruitment. Congrats to A/Prof Peter Grimison & the entire #P3BEP team for this important #GermCellCancerresearch Cancer Research UK Cambridge University Hospitals NHS #ANZCHOG Children’s Oncology Group NHMRC CTC Cancer Australia Ian Davis

More than surprised to see Pankaj Kumar Panda at my front gate 20 min before kick off, rather than in Singapore, where he lives and was supposed to be! #BestKeptSecret #LoveliestSurprise